retatrutide clinical trials phase Eli Lilly's 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide clinical trial dosing retatrutide

In a phase 2, randomized, double-blind, placebo-controlled trial of 10 g RM-131 involving 204 patients with diabetic gastroparesis (12% type 1 diabetes mellitus, 88% type 2 diabetes mellitus), with a 28-day treatment period after a 1-week, single-blinded, placebo run-in, RM-131 enhanced gastric emptying and reduced vomiting episodes and vomiting severity

McClean PL, Holscher C

In the SELECT trial, Semaglutide 2.4 mg reduced the risk of kidney events in people with obesity and without T2D

Dizziness is a recognised side effect of GLP-1 receptor agonists, though the frequency varies between different products

Long-term fracture data on women who've been on semaglutide or tirzepatide for three or more years doesn't yet exist in published form

This GTPase and translation termination factor is one of several usual suspect CRBN (cereblon) neosubstrates